Application Number 10506307

	, фриовион гининон		10000001	
	Filing Date		2007-04-19	
	First Named Inventor BIS		BISSONNETTE, Luc	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1634	
	Examiner Name	GREE	NE, JAIME	
	Attorney Docket Number	er	056694-0010	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Dat	te	Name of Pate of cited Docu	entee or Applicant ment	Releva		ines where s or Releva
	1	6197941		2001-03-0	16	ZAMPONI, et a	ai			
	2	6589731		2003-07-0	18	CHEN, et al	- 1			
If you wisi	h to a	dd additional U.S. Pate	nt citatio	n informati	ion pl	ease click the	Add button.		Add	
			U.S.P	ATENT A	PPLIC	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	on	Name of Patentee or Applicat of cited Document		Releva		ines where s or Releva
	1	20020177136		2002-11-2	18	MCBRANCH,	et al			
	2	20030152995		2003-08-1	4	HANNAH				
	3	20020068295		2002-06-0	16	MADOU, et al				
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication c	itation	n information p	lease click the Ad	d button.	Add	
				FOREIGN	I PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Gind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	ages,Colu here Relevassages o	ant Relevant

| Application Number | 10969597 | Filing Date | 2007-04-10 | Filing Named Inventor | BISSONNETTE, Luc | Art Unit | 1634 | Examiner Name | GREENE, JAMIE | Attorney Docket Number | 006694-0010 | Comment | Comme

	1	WO02081735			2002-10-17	LECLERC, et al		
	2	WO02095052			2002-11-28	HYLDIG-NIELSEN, et al		
	3	WO9802499			1998-01-29	LECLERC, et al		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T5	
	1	ALIVISATOS, P., Pure Appl. Chem., Vol 72, Nos. 1-2, pp. 3-9, 2000						
	2	BEAUCAGE, S., Curr Med Chem, Vol. 8, No. 10, pp. 1213-1244, 2001						
	3	BEIER, M. and HOHEISEL, J., Nucleic Acids Research, 1999, Vol 27, No. 9 pp. 1970-1977						
	4	BRANDT, O. et al., Nucleic Acids Research, 2003, Vol. 31, No. 19						
	5	BRANDT, O. and HOHE	ISEL, J., TRENDS	S in Biot	echnology, Vol. :	22, No. 12, December 2004		
	6	BRAUN, E. et al., Nature, Vol. 391, 19 February 1998 pp. 775-778						

	Application Number		10596397	-
	Filing Date		2007-04-19	-
INFORMATION DISCLOSURE	First Named Inventor	BISS	ONNETTE, Luc	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1634	
Not for submission under 37 of K 1.337	Examiner Name	GREE	ENE, JAIME	
	Attorney Docket Number		056694-0010	
			7	_

	7	BRUST, M. and KIELY, C., Colloids and Surfaces A: Physicochem, Eng. Aspects 202, 2002, 175-186	
	8	CHAN, W. and NIE, S., Science, Vol. 281, 25 Sept. 1998, pp. 2016-2018	
	9	COFFER, J., et al., Appl. Phys. Left. 69 (25):3851 December 1996	
	10	Elbashir, S. et al., The EMBO Journal, Vol. 20 No. 23 PP 6877-6888, 2001	
	11	FREDRICKS, D. and RELMAN, D. Clinical Infectious Diseases, Vol 29, pp. 475-88, 1999	
	12	FREIER, S.M. et al., Proc. Natl. Acad. Sci. USA, Vol. 83 pp. 9373-9377, December 1986	
	13	GAYLORD, B. et al., Proc. Natl. Acad. Sci. Vol. 96, No. 17, pp. 10954-10957, August 20, 2002	
	14	GERMINI, A. et al., J Agric. Food Chem. Vol. 52, pp. 4535-4540, 2004.	
	15	HO, H. et al., Agnew. Chem. Int. Ed. Vol. 41, No. 9, pp. 1548-155, 2002	
	16	HO, H. et al., Polymer Preprints 2002, Vol. 43, No. 1, pp. 133-34	

HUANG, J. et al., Polymer Bulletin, Vol. 36, pp. 337-340, 1996

Application Number 10596397		
Filing Date 2007-04-19		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor BISSONNETTE, Luc		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit 1634	1634	
Examiner Name GREENE, JAIME		
Attorney Docket Number 056694-0010		

	18	JAIN, K. Pharmacogenomics 2000, Vol. 1, No. 3, pp. 289-307	
	19	KRICKA, L. J., Ann Clin Blochem 2002, Vol. 39 pp. 114-129	
	20	KRISHNAMOORTHY, K. et al., Chem Commun, 2004, pp. 820-821	
	21	KWOH, D.Y. et al., Proc Natl Acad Sci USA, Vol. 86, pp. 1173-1177, February 1989	
	22	KWOH, B. and KWOH, J. Am Biotechnol Lab 1990, pp. 14-25	
	23	LIU, A, and ANZAI, J. ANai Chem 2004, Vol. 76, pp. 2975-2980	
	24	LIZARDI, P. et al., Biotechnology, Vol. 6, October 1988 pp. 1197-1202	
	25	MALEK, L. et al., Methods in Molecular Biology, Vol. 28, pp. 253-260	
	26	PENNER, R. Acc Chem Res 2000, Vol. 33, pp. 78-86	
	27	PORATH, J. Method Enzymol. pp. 13-30, 1974	
	28	RAY, A. and NORDEN, B. The FASEB Journal, Vol. 14, pp.1041-1060, June 2000	П

	Application Number		10596397		
	Filing Date		2007-04-19		
INFORMATION DISCLOSURE	First Named Inventor	First Named Inventor BISSONNETTE, Luc			
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1634		
Not for submission under 37 GFR 1.337	Examiner Name	GREE	ENE, JAIME		
	Attorney Docket Numb	er	056694-0010		
				_	

	29	REYNOLDS, M. et al., Nucleic Acids Research, Vol. 24, No. 22, pp. 4584-4591, 1996	
	30	ROSSETTO, F. and NIEBOER, E., Journal of Inorganic Biochemistry, Vol. 54, pp. 167-186, 1994	
	31	STORHOFF, J. and MIRKIN, C., Chem Rev 1999, Vol. 99, pp. 1849-1862	
	32	TURNER, D. et al., J. Am Chem Soc 1987, Vol. 109, pp. 3783-3785	
	33	VO-DINH, T. and CULLUM, B. Fresenius J Anal Chem, 2000, Vol. 366, pp. 540-551	
	34	WARNER, M.G. and HUTCHISON, J. E., Nature Materials, Vol. 2, pp. 272-277, April 2003	
	35	DORE, et al., J. Am. Chem Soc 7, Vol 126:13 pp. 4240-4244, April 2004	
	36	FRITZ, J. et al., Proc. Natl Acad Sci., Vol 99, No. 22, pp. 14142-14146, October 2002	
	37	HO, H. et al., J Am Chem Soc., Vol 126: 1384-1387, 2004	
	38	LUKKARI, J. et al., J Am Chem Soc., Vol 123:6083-6091, 2001	
	39	NIELSEN, P. et al., Current Issues Molec Biol., Vol 1, No 2, pp. 89-104, 1999	

| NFORMATION DISCLOSURE | Filing Date | 10569597 | Filing Date | 2007-04-19 | Filing Named Inventor | BISSCNNETTE, Ltd Art Unit | 1634 | Art Unit | 1634 | Examiner Name | GREENE, JAMEE | Attorney Docket Number | 056969-04010 | Control of the C

	40	NILSSON, K., et at., Nature Materials, Vol 2-419-424, June 2003		
	41	ON, K., et al., Proc natl Acad Sci USA, Vol. 100, No. 18, pp. 10170-10174, September 2, 2003		
	42	SASTRY, M., Pure Appl Chem., Vol. 74, No. 9, pp. 1621-1630, 2002		
	43	ZIAO, S., et al., J Nanoparticle Res., Vol. 126:1384-1387, 2004		
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add		
		EXAMINER SIGNATURE		
Examiner	Signa	ure Date Considered		
		ial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thro	ough a	

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the hor-letter code (WIPO Standard ST.3.). ³ For Japanese patent documents, the indication of the year of the respond the Emperor must precode the sens number of the patent document. ⁴ Hond of document by the perpoperate symboles as enclusion for the document under WIPO Standard ST if Spoasio. ⁸ Applicant is to place a checked.

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596397
Filing Date		2007-04-19
First Named Inventor	BISS	ONNETTE, Luc
Art Unit		1634
Examiner Name GREE		ENE, JAIME
Attorney Docket Number		056694-0010

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s):
---------------	----------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Nicholas A. Kees/	Date (YYYY-MM-DD)	2007-08-13
Name/Print	Nicholas A. Kees	Registration Number	29552

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be discbesed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.